| Mechanisms to explain surfactant responses. | |
| | |
MedLine Citation:
|
PMID: 16770069 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Surfactant is now standard of care for infants with respiratory distress syndrome. Surfactant treatments are effective because of complex metabolic interactions between surfactant and the preterm lung. The large treatment dose functions as substrate; it is taken up by the preterm lung and is reprocessed and secreted with improved function. The components of the treatment surfactant remain in the preterm lung for days. If lung injury is avoided, then surfactant inhibition is minimized. Prenatal corticosteroids complement surfactant to further enhance lung function. The magic of surfactant therapy results from the multiple interactions between surfactant and the preterm lung. |
| | |
Authors:
|
Alan H Jobe |
Related Documents
:
|
15173479 - Timing of initial surfactant treatment for infants 23 to 29 weeks' gestation: is routin... 15466069 - Respiratory syncytial virus hospitalizations among american indian and alaska native in... 4051409 - Differentiating upper from lower airway compromise in neonates. 6243929 - Familial infantile myasthenia. 23432339 - Pharmacokinetics of melatonin in preterm infants. 17253569 - Postnatal thyroid hormones for respiratory distress syndrome in preterm infants. 11213929 - Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes. 23056829 - The clinical and bacteriogical spectrum of neonatal sepsis in a tertiary hospital in ya... 23220549 - Nutritional rickets around the world. |
Publication Detail:
|
Type: Journal Article; Review Date: 2006-06-01 |
Journal Detail:
|
Title: Biology of the neonate Volume: 89 ISSN: 0006-3126 ISO Abbreviation: Biol. Neonate Publication Date: 2006 |
Date Detail:
|
Created Date: 2006-06-13 Completed Date: 2006-10-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0247551 Medline TA: Biol Neonate Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 298-302 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2006 S. Karger AG, Basel. |
Affiliation:
|
Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, Ohio, USA. alan.jobe@cchmc.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
metabolism Animals Gestational Age Humans Infant, Newborn Organ Size / drug effects Pulmonary Surfactants / pharmacology*, therapeutic use* Respiratory Distress Syndrome, Newborn / drug therapy, metabolism, pathology Surface-Active Agents / pharmacology*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones; 0/Pulmonary Surfactants; 0/Surface-Active Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lung disease and brain development.
Next Document: Progress in discovery and evaluation of treatments to prevent bronchopulmonary dysplasia.